Specific inhibition of PRMT5 suppresses human CD8+T cells by upregulation of p53 and impairment of the AKT pathway similar to the tumor metabolite MTA

Strobl C, Schaffer S, Völkl S, Haug T, Peter K, Böttcher M, Mougiakakos D, Mackensen A, Aigner M (2019)

Publication Language: English

Publication Type: Conference contribution, Abstract of a poster

Publication year: 2019

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

Series: ONCOLOGY RESEARCH AND TREATMENT

City/Town: BASEL

Book Volume: 42 (Suppl. 4)

Pages Range: 276

Event location: Berlin DE

DOI: 10.1159/000502425

Authors with CRIS profile

Carolin Strobl Department of Medicine 5 – Haematology and Oncology Simon Völkl Department of Medicine 5 – Haematology and Oncology Martin Böttcher Department of Medicine 5 – Haematology and Oncology Dimitrios Mougiakakos Professur für CAR-T-Zell-Therapie Andreas Mackensen Lehrstuhl für Innere Medizin V

Involved external institutions

Universitätsklinikum Regensburg DE Germany (DE)

How to cite

APA:

Strobl, C., Schaffer, S., Völkl, S., Haug, T., Peter, K., Böttcher, M.,... Aigner, M. (2019, October). Specific inhibition of PRMT5 suppresses human CD8+T cells by upregulation of p53 and impairment of the AKT pathway similar to the tumor metabolite MTA. Poster presentation at Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie 2019, Berlin, DE.

MLA:

Strobl, Carolin, et al. "Specific inhibition of PRMT5 suppresses human CD8+T cells by upregulation of p53 and impairment of the AKT pathway similar to the tumor metabolite MTA." Presented at Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie 2019, Berlin BASEL: KARGER, 2019.

BibTeX: Download